Conservation of functional domains and limited heterogeneity of HIV-1 reverse transcriptase gene following vertical transmission

Table 1 Demographic, Clinical, and Laboratory Parameters of HIV-1 Infected Mother-Infant Pairs

Patient	Age	Sex	CD4+ cells/mm3	Length of infection ^a	Antiviral drug	Clinical Evaluation ^b
MB	28 yr		509	11 mo	None	Asymptomatic
IB	4.75 mo	M	1942	4.75 mo	None	Asymptomatic, P1A
MC	23 yr		818	1 yr6 mo	None	Asymptomatic
IC	14 mo	F	772	14 mo	ZDV	Symptomatic AIDS;P2A,D1,3,F
MD	31 yr		480	2 yr6 mo	None	Asymptomatic
ID	28 mo	M	46	28 mo	ddC^c	Symptomatic AIDS, P2AB,F; failed ZDV therapy
MF	23 yr		692	2 yr10 mo	None	Asymptomatic
IF	1 wk	M	2953	1 wk	ZDV	Asymptomatic,P1A
MH	33 yr		538	5 mo	None	Asymptomatic
IHT1	7 mo	F	3157	7 mo	ACTG152	Hepatosplenomeglay lymphadenopathy
IHT2	7 mo	F	2176	7 mo	ACTG152	Hepatosplenomegaly lymphadenopathy

M: mother; I: infant. ^aLength of infection: The closest time of infection that we could document was the first positive HIV-1 serology date or the first visit of the patient to the AIDS treatment Center, where all the HIV-1 positive patients were referred to as soon as an HIV-1 test was positive. Therefore, these dates may not reflect the exact dates of infection.
^b Evaluation for infants is based on CDC criteria, ^cddC, Zalcitibine